New BioMedicine Special Event Report
Anadys Pharmaceuticals, Inc. (ANDS) - Preliminary data from the Phase II trial of ANA598 for Hepatitis C Virus (HCV) Infection
| Date: | Sep 21, 2009 |
|---|---|
| Format: | |
| Price: | $40.00 |
Abstract
Event-based Healthcare Investment Report for Anadys Pharmaceuticals, Inc. (ANDS) - Preliminary data from the Phase II trial of ANA598 for Hepatitis C Virus (HCV) Infection
New BioMedicine Biotech Research Report provides in-depth analysis relating to an upcoming event for a select pipeline drug. The report forecasts the expected event outcome (positive/negative), and discusses the relevant company, the drug candidate, market opportunity, clinical trials results, and competitive landscape.
The Biotech Research Report is unique in its focus on events likely to drive large price movements within narrow timeframes, and because it forecasts event outcomes based on rigorous analysis of clinical results and regulatory factors.
Companies Mentioned in the Report
More Information:
Learn more about New BioMedicine Event Report.